This promotional video is funded and reviewed by Bayer Consumer Care AG for healthcare professionals only. This video is not intended for UK healthcare professionals.
The views expressed are those of the named speaker.
EU Prescribing information for Lynkeut▼ (elinzanetant) can be found here. Please refer to local prescribing information in your country of practice before prescribing, as information and indications may vary. ▼This medicinal product is subject to additional monitoring in the EU and other countries. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse event reporting information can be found at the end of this webpage.
Vasomotor symptoms (VMS) can significantly affect the quality of life for women with breast cancer receiving adjuvant endocrine therapy, yet treatment options remain limited.1-3
As healthcare professionals, addressing these persistent symptoms is an important part of delivering truly patient-centred care.
Data from the OASIS-4 trial, highlighting the efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy were first delivered as an oral presentation at ASCO 2025 and are now published.⁴
Key Takeaways:
- OASIS-4 is the first pivotal randomised, placebo-controlled, Phase III trial of a neurokinin-targeted therapy in women suffering from disruptive menopause symptoms caused by their adjuvant endocrine therapy for breast cancer4,5
- Elinzanetant provided significant improvements in VMS frequency,† sleep disturbances,‡ and menopause-related quality of life,‡ showed greater reductions in VMS severity,§ and had a favourable safety and tolerability profile in this patient population4
†Primary endpoint; ‡Key secondary endpoint; §Additional secondary endpoint;
In this video, Fatima Cardoso, the lead investigator, provides an overview of the study findings and their potential clinical implications.
This dedicated segment is now available to watch online and offers valuable context to complement the published data.
Speaker:
Fatima Cardoso1
1. Senior Consultant, Medical Oncology, President, ABC Global Alliance, Lisbon, Portugal
Elinzanetant is the first dual neurokinin 1 and 3 (NK1, 3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate-to-severe VMS associated with menopause or caused by adjuvant endocrine therapy, administered orally once daily. Latest science indicates that targeted dual blockade of NK1 and NK3 receptors in the hypothalamus and of NK1 receptors in the skin brings balance back to temperature regulation and sleep.2,4,6
| Adverse events should be reported. Reporting forms and information for the EU can be found here. Adverse events should also be reported to Bayer via Safe Track. |
References
- The North American Menopause Society (NAMS) 2023 Nonhormone Therapy Position Statement Advisory Panel. The North American Menopause Society (NAMS) 2023 Nonhormone Therapy Position Statement Advisory Panel. Menopause 2023;30(6):573–90.
- Simon JA et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023;30(3):239–46.
- Kingsberg S et al. Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: real-world findings from the United States and Europe. Maturitas 2024;188:108071.
- Cardoso F et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med. 2025;DOI:10.1056/NEJMoa2415566 (including supplementary appendix).
- Bayer. Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for the treatment of moderate to severe vasomotor symptoms caused by breast cancer. 2025. Available at: https://www.bayer.com/media/en-us/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4-for-treatment-of-moderate-to-severe-vasomotor-symptoms-caused-by-breast-cancer-treatments/. Last accessed: 30 May 2025.
- Pinkerton JAV et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-54.
This information is intended for healthcare professionals only. For Educational purposes only.
MA-LNK-ALL-0004-1 July 2025
